Shares of Sanofi (NYSE:SNY) fell 0.3% on Friday . The company traded as low as $40.82 and last traded at $40.85, with a volume of 617,239 shares traded. The stock had previously closed at $40.99.

A number of research firms have recently weighed in on SNY. Zacks Investment Research cut Sanofi from a “buy” rating to a “hold” rating in a research report on Monday, June 6th. JPMorgan Chase & Co. restated a “sell” rating on shares of Sanofi in a research note on Monday, March 14th. Citigroup Inc. restated a “neutral” rating on shares of Sanofi in a research note on Wednesday, April 27th. HSBC lowered Sanofi from a “buy” rating to a “hold” rating in a research note on Tuesday, May 3rd. Finally, Bank of America Corp. restated a “buy” rating and issued a $58.00 target price on shares of Sanofi in a research note on Tuesday, May 3rd. Four investment analysts have rated the stock with a sell rating, six have given a hold rating and five have assigned a buy rating to the company’s stock. Sanofi has a consensus rating of “Hold” and a consensus price target of $49.67.

The firm’s 50-day moving average price is $40.28 and its 200-day moving average price is $40.77. The company has a market capitalization of $105.27 billion and a price-to-earnings ratio of 22.18.

A number of institutional investors have bought and sold shares of the stock. Morgan Stanley raised its position in Sanofi by 34.9% in the fourth quarter. Morgan Stanley now owns 3,660,972 shares of the company’s stock valued at $156,140,000 after buying an additional 946,483 shares during the period. Seminole Management Co. Inc. acquired a new position in Sanofi during the fourth quarter valued at approximately $26,208,000. Tekla Capital Management LLC acquired a new position in Sanofi during the fourth quarter valued at approximately $13,008,000. Freestone Capital Holdings LLC acquired a new position in Sanofi during the fourth quarter valued at approximately $1,672,000. Finally, First Trust Advisors LP raised its position in Sanofi by 25.9% in the fourth quarter. First Trust Advisors LP now owns 163,637 shares of the company’s stock valued at $6,979,000 after buying an additional 33,688 shares during the period.

Sanofi SA is a healthcare company focused on patient needs and engaged in the research, development, manufacture and marketing of healthcare products. The Company is organized around three principal activities: Pharmaceuticals, Human Vaccines via Sanofi Pasteur, and Animal Health via Merial. The Company invests in emerging markets, diabetes solutions, vaccines, consumer health care, animal health, genzyme and other products.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.